Please use this identifier to cite or link to this item: http://hdl.handle.net/2381/38563
Title: Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial.
Authors: Davies, M. J.
Russell-Jones, D.
Selam, J. L.
Bailey, T. S.
Kerényi, Z.
Luo, J.
Bue-Valleskey, J.
Iványi, T.
Hartman, M. L.
Jacobson, J. G.
Jacober, S. J.
IMAGINE 2 Study Investigators
First Published: 12-Aug-2016
Publisher: Wiley
Citation: Diabetes, Obesity and Metabolism, 2016, 18 (11), pp. 1055-1064
Abstract: AIMS: To compare, in a double-blind, randomized, multi-national study, 52- or 78-week treatment with basal insulin peglispro or insulin glargine, added to pre-study oral antihyperglycaemic medications, in insulin-naïve adults with type 2 diabetes. MATERIAL AND METHODS: The primary outcome was non-inferiority of peglispro to glargine with regard to glycated haemoglobin (HbA1c) reduction (margin = 0.4%). Six gated secondary objectives with statistical multiplicity adjustments focused on other measures of glycaemic control and safety. Liver fat content was measured using MRI, in a subset of patients. RESULTS: Peglispro was non-inferior to glargine in HbA1c reduction [least-squares (LS) mean difference: -0.29%, 95% confidence interval (CI) -0.40, -0.19], and had a lower nocturnal hypoglycaemia rate [relative rate 0.74 (95% CI 0.60, 0.91); p = .005), more patients achieving HbA1c <7.0% without nocturnal hypoglycaemia [odds ratio (OR) 2.15 (95% CI 1.60, 2.89); p < .001], greater HbA1c reduction (p < .001), and more patients achieving HbA1c<7.0% [OR 1.97 (95% CI 1.57, 2.47); p < .001]. Total hypoglycaemia rate and fasting serum glucose did not achieve statistical superiority. At 52 weeks, peglispro-treated patients had higher triglyceride (1.9 vs 1.7 mmol/L). alanine transaminase (34 vs 27 IU/L), and aspartate transaminase levels (27 vs 24 IU/L). LS mean liver fat content was unchanged with peglispro at 52 weeks but decreased 3.1% with glargine [difference: 2.6% (0.9, 4.2); p = .002]. More peglispro-treated patients experienced adverse injection site reactions (3.5% vs 0.6%, p < .001). CONCLUSIONS: Compared with glargine at 52 weeks, peglispro resulted in a statistically superior reduction in HbA1c, more patients achieving HbA1c targets, less nocturnal hypoglycaemia, no improvement in total hypoglycaemia, higher triglyceride levels, higher aminotransferase levels, and more injection site reactions.
DOI Link: 10.1111/dom.12712
ISSN: 1462-8902
eISSN: 1463-1326
Links: http://onlinelibrary.wiley.com/doi/10.1111/dom.12712/abstract
http://hdl.handle.net/2381/38563
Version: Publisher Version
Status: Peer-reviewed
Type: Journal Article
Rights: © 2016 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Description: Additional Supporting Information may be found in the online version of this article at the publisher’s web-site: http://onlinelibrary.wiley. com/doi/10.1111/dom.12712/suppinfo.
Appears in Collections:Published Articles, Dept. of Cardiovascular Sciences

Files in This Item:
File Description SizeFormat 
Davies_et_al-2016-Diabetes,_Obesity_and_Metabolism.pdfPublished (publisher PDF)972.8 kBAdobe PDFView/Open


Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.